knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 17:20:58 - browse：18

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

WSS

Advances in CAR

Amazon on where the company's health care bets are headed next

Crinetics acromegaly drug succeeds in late

CMS should re

Chemotherapy shortages won’t get better under Biden’s latest plan

AI models in health care face new federal disclosure requirements

focus

knowledge

focus

In age of alternative facts, a scholarly course on calling out crap

Pfizer plans to depart BIO

United colonoscopy coverage change 'may cost lives,' doctors say

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Supreme Court strikes down use of affirmative action

What causes an itch? Researchers may have solved the mystery

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AstraZeneca chief proposes a novel edit to the drug pricing bill

Activists slam private health insurers over coverage restrictions

Why Novartis is changing the name of its research labs

focus

Weighted lottery helped low

Amazon on where the company's health care bets are headed next

Spinal cord stimulation reduces pain in amputees, study finds

What drug price negotiations mean for Medicare Part D

NIH nominee Bertagnolli will get October confirmation hearing

What American doctors can learn from their Israeli counterparts

explore

Wikipedia

focus

knowledge